A Cedars-Sinai Heart Institute patient became the first in the nation to undergo the newly approved non-surgical procedure to fix their leaky and life-threatening heart valve condition.
The Cardiovascular Research Foundation (CRF) and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced the initiation of the Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT II) trial and the PROSPECT ABSORB sub study.
The U.S. Food and Drug Administration (FDA) approved Cardiovascular Systems Inc.’s Diamondback 360 Coronary Orbital Atherectomy System (OAS) for treatment of patients with severely calcified coronary lesions and who are candidates for percutaneous transluminal coronary angioplasty (PTCA) and have previously not been treated.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Corindus Vascular Robotics, a provider of precision medical robotics, announced the launch of its CorPath One Stent Program.
PHS Technologies Group LLC, a division of PACSHealth LLC, announced that it has been awarded a group purchasing agreement with Premier, Inc. for DoseMonitor, its radiation dose tracking system.
Abbott announced clinically meaningful changes to quality of life, a reduction in rehospitalization for heart failure, and functional improvements for patients treated with the company's first-in-class, catheter-based MitraClip therapy for patients with degenerative mitral regurgitation (MR). Findings were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco and simultaneously published in the Journal of the American College of Cardiology.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
The American College of Radiology (ACR) applauded a joint Senate Finance and House Committee on Ways and Means’ proposal to require ordering physicians to consult appropriateness criteria for advanced imaging services provided to Medicare patients.
The Boston Scientific Corp. Lotus Valve System met a performance measure in the treatment of symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement, according to new data released at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013) in San Francisco.
MedStar Heart Institute of Washington, D.C. and Infraredx, Inc. announced the initiation of the Lipid-Rich Plaque (LRP) Study, a prospective, multi-center study designed to evaluate the ability of intravascular imaging to identify patients with LRPs who are at a higher risk for heart attacks and other serious coronary events.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Cerner’s PowerChart cardiovascular solution unifies diagnostic cardiology activities, therapeutic interventions and follow-up regimens into a unified electronic health record (EHR) for the patient. This greatly simplifies workflow and enables cardiologists to see a consolidated view of clinical information from within Cerner’s EHR, PowerChart. Cerner’s partnership with Merge Cardio and Merge Hemo provides cardiac imaging for catheterization, intravascular ultrasound, echocardiography and nuclear medicine; facilitates structured reporting for cardiologist clinical interpretations; and integrates hemodynamics data with the Cerner EMR.
MedCurrent Corp. will debut OrderRight 3.0 at the Radiological Society of North America’s Annual Meeting (RSNA), December 1-5, 2013 at Chicago’s McCormick Place. MedCurrent will exhibit in the South Hall, booth #3106.
According to a study of diabetic patients who underwent revascularization for multivessel coronary artery disease (CAD), patients treated with insulin experienced more major adverse cardiovascular events after revascularization than those not treated with insulin.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
A new study demonstrated that some patients may not need to receive prolonged anti-clotting therapy after drug-eluting stent (DES) implantation with the Endeavor zotarolimus-eluting stent, and that shortening the duration could reduce bleeding risks and treatment costs.
According to a new study, aspirating blood clots does not significantly reduce microvascular obstruction or reduce the risk of death in patients with non-ST-elevation myocardial infarction (NSTEMI), when compared to standard percutaneous coronary intervention (PCI) without thrombectomy. Findings from the TATORT-NSTEMI clinical trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual antiplatelet therapy (DAPT) according to the results from the ARCTIC-INTERRUPTION trial, which was presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).